Cargando…
Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients
Objective to evaluate the clinical efficacy and safety of sacubitril valsartan in the treatment of heart failure (HF) with midrange ejection fraction after acute myocardial infarction (AMI) in diabetic patients. From January 2015 to July 2020, HF patients with diabetes mellitus complicated with AMI...
Autores principales: | Ye, Fanhao, Li, Hebo, Chen, Xiaoshu, Wang, Yi, Lin, Wei, Chen, Hao, Huang, Shiwei, Han, Sisi, Guan, Fanlu, Huang, Zhouqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812610/ https://www.ncbi.nlm.nih.gov/pubmed/35119021 http://dx.doi.org/10.1097/MD.0000000000028729 |
Ejemplares similares
-
Sacubitril/Valsartan for heart failure: A protocol for systematic review and meta-analysis
por: Dai, Wenqin, et al.
Publicado: (2022) -
Use of sacubitril/valsartan in Marfan syndrome–related cardiomyopathy: The first case report
por: Spoto, Silvia, et al.
Publicado: (2019) -
Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption: A STROBE-compliant study
por: Chen, Wenwen, et al.
Publicado: (2021) -
Left atrial diameter in heart failure with left ventricular preserved, mid-range, and reduced ejection fraction
por: Zhu, Ning, et al.
Publicado: (2019) -
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)